Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GSK’s respiratory syncytial virus older adult vaccine candidate granted Priority Review by US FDA
The US FDA has accepted a Biologics License Application and granted Priority Review for its RSV older adult vaccine candidate.
GSK delivers strong Q3 2022 sales of £7.8 billion +18% AER, +9% CER and Total EPS 255.9p +>100% AER, +>100% CER; Adjusted EPS of 46.9p +25% AER, +11% CER
Strong commercial execution drives continued sales growth across Specialty Medicines, Vaccines and General Medicines
European Medicines Agency validates ViiV Healthcare’s marketing authorisation application for cabotegravir long-acting injectable for HIV Prevention
The marketing application is based on results from the HPTN 083 and 084 phase IIb/III studies.
GSK marketing authorisation application for respiratory syncytial virus older adult vaccine candidate accepted by European Medicines Agency under accelerated assessment
The vaccine was well tolerated with a favourable safety profile.
GSK provides update on ContRAst phase III programme for otilimab in the treatment of moderate to severe rheumatoid arthritis
Full results from the ContRAst phase III programme will be submitted for publication in 2023.
GSK reports outcome from US FDA Advisory Committee meeting on daprodustat for anaemia of CKD
Daprodustat was studied in the ASCEND phase III clinical trial programme.
ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV
Data from the BANNER study show antiviral efficacy, safety, and tolerability of N6LS, supporting its continued study in phase IIb
GSK regulatory submission accepted by Japanese regulator for respiratory syncytial virus older adult vaccine candidate
The proposed indication is for adults aged 60 years and above to prevent lower respiratory tract diseases (LRTD) caused by RSV.
New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over
The ZOSTER-049 extension study shows that Shingrix can provide at least a decade of protection against shingles after initial vaccination
GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D
GSK will work together with Tempus to improve clinical trial design, speed up enrolment and identify drug targets.
US FDA approves Menveo in a new single-vial presentation to help prevent disease caused by meningococcal bacteria serogroups A, C, Y, and W
The Menveo one-vial presentation now comes in a ready to use single vial giving healthcare providers a more convenient option.
GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
Data showed overall vaccine efficacy against RSV-lower respiratory tract disease in adults aged 60 years and above
GSK to present updates on its industry-leading infectious disease portfolio at IDWeek 2022
GSK will share updates on its industry-leading infectious disease pipeline and portfolio with 33 abstracts accepted for IDWeek 2022.
US FDA approves BOOSTRIX for immunisation during pregnancy for the prevention of whooping cough in newborn infants
The US FDA has approved Boostrix for immunisation during the third trimester of pregnancy to help prevent pertussis (whooping cough).
GSK announces positive headline results from PERLA, the phase II trial of Jemperli (dostarlimab) plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer
The PERLA phase II trial is the largest global head-to-head trial of programmed death receptor-1 (PD-1) inhibitors in this population.
Iain Mackay, Chief Financial Officer, to retire from GSK, Julie Brown appointed as successor
The Board has selected Ms Julie Brown, currently Chief Operating and Financial Officer, Burberry Group plc, as successor to Iain Mackay.
Oncologic Drugs Advisory Committee to review Zejula overall survival data from the NOVA phase III trial in recurrent ovarian cancer
The US FDA will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to discuss overall survival data from the Nova trial
GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a late-stage antibiotic that may treat complicated urinary tract infections
GSK has entered into an exclusive license agreement with Spero Therapeutics for tebipenem pivoxil HBr.
GSK and Microsoft, in collaboration with the Centre for Health and Disease Studies, launch disease surveillance project in Nepal
New partnership combines expertise across Biopharma and Tech sectors.
GSK launches Sustainable Procurement Programme for suppliers
From 2023, the company will require and support suppliers to take action on sustainability commitments.